Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2015 | Research

Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis

Authors: Yi Yang, Zihao Wang, Yiming Zhou, Xiaoxiao Wang, Jianbin Xiang, Zongyou Chen

Published in: World Journal of Surgical Oncology | Issue 1/2015

Abstract

Background

Interleukin (IL)-32 is a described intracellular pluripotent pro-inflammatory mediator, characterized by the signaling of NF-κB and STAT3.

Methods

Our study investigated whether IL-32 expression has clinical significance in the metastases of colorectal cancer (CRC). A total of 70 CRC patients were enrolled, 47 cases of which were single CRC organic metastasis lesions while the rest of which were primary CRC lesions (T4NxM0). IL-32 expression was detected by immunohistochemistry, and the correlation between IL-32 expression and CRC metastases was analyzed.

Results

The positive rates of IL-32 in the CRC organic metastasis group were more severe than those in the primary CRC group (P < 0.05). The positive rate of IL-32 in primary CRC with lymph node metastasis was more severe than that of IL-32 in primary CRC without lymph node metastasis (P < 0.05).

Conclusions

The level of IL-32 expression could influence the N grade of CRC. Thus, IL-32 expression may stimulate the organic metastasis and the lymph node metastasis of CRC.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61C:69–90.

Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMed

Midgley R, Kerr D. Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs. 2001;10:1011–9.CrossRefPubMed

Ferlay J, Shin HR, Bray F, Forman D, Mathers C. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Canc Suppl J Int Canc. 2010;127:2893–917.CrossRef

Mitry E, Bouvier AM, Esteve J, Faivre J. Benefit of operative mortality reduction on colorectal cancer survival. Br J Surg. 2002;89:1557–62.CrossRefPubMed

Sethi N, Kang Y. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat Rev Canc. 2011;11:735–48.CrossRef

Wanebo HJ, LeGolvan M, Paty PB, Saha S, Zuber M. Meeting the biologic challenge of colorectal metastases. Clin Exp Metastasis. 2012;29:821–39.CrossRefPubMed

Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175–83.CrossRefPubMedCentralPubMed

Ting WC, Chen LM, Huang LC, Hour MJ, Lan YH, Lee HZ, et al. Impact of interleukin-10 gene polymorphisms on survival in patients with colorectal cancer. J Korean Med Sci. 2013;28(9):1302–6.CrossRefPubMedCentralPubMed

10.

Petanidis S, Anestakis D, Argyraki M, Hadzopoulou-Cladaras M, Salifoglou A. Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-γ. PLoS One. 2013;8(9):e73616.CrossRefPubMedCentralPubMed

11.

Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol. 2013;6(9):1806–16.PubMedCentralPubMed

12.

Jung MY, Son MH, Kim SH, Cho D, Kim TS. IL-32gamma and Streptococcus pyogenes cell wall fragments synergise for IL-1-dependent destructive arthritis via upregulation of TLR-2 and NOD2. Ann Rheum Dis. 2010;69:1866–72.CrossRef

13.

Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit CareMed. 2008;178:894–901.CrossRef

14.

Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNF alpha. Immunity. 2005;22:131–42.PubMed

15.

Conti P, Youinou P, Theoharides TC. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev. 2007;6:131–7.CrossRefPubMed

16.

Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ, et al. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol. 2008;9:1606–12.

17.

Nishida A, Andoh A, Inatomi O, Fujiyama Y. Interleukin-32 expression in the pancreas. J Biol Chem. 2009;284(26):17868–76.CrossRefPubMedCentralPubMed

18.

Sorrentino C, Di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med. 2009;180(8):769–79.CrossRefPubMed

19.

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.CrossRefPubMed

20.

Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38–52.CrossRefPubMed

21.

Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66:5527–36.CrossRefPubMed

22.

Yun HM, Oh JH, Shim JH, Ban JO, Park KR, Kim JH, et al. Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals. Cell Death Dis. 2013;4:e640.CrossRefPubMedCentralPubMed

23.

Yousif NG, Al-Amran FG, Hadi N, Lee J, Adrienne J. Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine. 2013;1(1):223–27.CrossRef

24.

Oh JH, Cho MC, Kim JH, Lee SY, Kim HJ, Park ES, et al. IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene. 2011;30(30):3345–59.CrossRefPubMedCentralPubMed

25.

Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer cell. 2009;15:283–93.CrossRefPubMedCentralPubMed

26.

Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol. 2011;186:3462–71.CrossRefPubMed

27.

Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ, et al. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol. 2008;18:1606–12.PubMed

Title: Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis
Authors: Yi Yang
Zihao Wang
Yiming Zhou
Xiaoxiao Wang
Jianbin Xiang
Zongyou Chen
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2015
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-015-0552-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer

Huge malignant phyllodes breast tumor: a real entity in a new era of early breast cancer

Hepatoid carcinoma of the pancreas

Clinicopathological characteristics, diagnosis, treatment, and outcomes of primary gastric adenosquamous carcinoma

Transarterial chemoembolization is ineffective for neuroendocrine tumors metastatic to the caudate lobe: a single institution review

Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status prediction in breast cancer patients with metastatic sentinel lymph nodes